In this video interview, Hagop Kantarjian, MD, speaks with Michael Mauro, MD, leader of the CML program at Memorial Sloan Kettering Cancer Center, on Dr. Mauro’s SOHO 2025 abstract on the phase 1a/b ENABLE trial investigating ELVN-001 in patients with previously treated chronic myeloid leukemia (CML).
In the interview, Dr. Mauro details patient’s response rates to the therapy, and the investigators’ dosing approach.
“ELVN-001 demonstrated favorable safety and tolerability across a wide range of doses, consistent with its selective kinase profile,” the investigators wrote in the abstract (CML-575). “Despite the heavily pretreated patient population, encouraging preliminary efficacy was observed.”
